3 résultats
Each subject will receive one infusion of autologous, radiolabeled and BioRBC labeled INTERCEPT RBCs (Test RBCs) and one infusion of autologous BioRBC labeled untreated RBCs (Control RBCs) concomitantly. Each infusion will be approximately 20 mL, i.e., 10 mL of 51-chromium labeled RBC, and 10 mL of
Summary. Subjects eligible for study include adult study subjects older than 18 years who had a positive antibody response to BioRBCs in previous BioRBC studies at the University of Iowa, Adult BioRBC Redosing Safety Protocol Page 3 of 6 but who are now BioRBC antibody sero-negative. The study will
Type 1 diabetes mellitus (T1D) is caused by autoimmune and autoinflammatory destruction of the insulin-producing beta cells in the pancreatic islets of Langerhans. Historically, treatment for this condition has consisted of insulin replacement therapy and dietary modification. Recent studies have